Particle.news

Molbio Diagnostics IPO Subscribed About 70x as Allotment Is Set Today

Strong institutional demand and large anchor subscriptions have increased expectations of a listing premium for the company’s Truenat point‑of‑care PCR business, heightening investor focus ahead of the debut.

Overview

  • The Rs 940 crore offer received about 70.26 times subscription after bidding closed on Wednesday, Aug. 12, with bids for 57,32,14,536 shares against 81,58,529 shares on offer.
  • Qualified institutional buyers drove demand, subscribing the QIB portion roughly 186.39 times while non‑institutional investors bid 49.80 times and retail investors about 12.96 times.
  • Molbio raised around Rs 281.5 crore from anchor investors before public bidding and structured the IPO as a fresh issue of up to Rs 200 crore plus an offer‑for‑sale within a Rs 768–807 price band.
  • The company said it will use fresh proceeds mainly for R&D infrastructure (about Rs 106 crore) and plant and machinery (about Rs 72 crore), with the remainder for general corporate purposes.
  • Unofficial grey‑market indicators have shown a premium (about Rs 154) suggesting a possible listing above the band but that signal is informal and the actual listing price will be known when Molbio lists on BSE and NSE on Aug. 17.